Skip to main content
Premium Trial:

Request an Annual Quote

Arcxis Lands $1M Homeland Security Award for DNA-Based Anthrax, Plague Dx

NEW YORK (GenomeWeb News) — Arcxis Biotechnologies has received a $1 million Phase II award from the US Department of Homeland Security to continue developing its BioPhalanx instrument, a portable, rapid-detection bio-threat analyzer, the company said Tuesday. 
 
The Pleasanton, Calif.-based company said the funding comes after it demonstrated a genomic probe assay for viruses causing anthrax and plague that does not report false positive results.
  
Arcxis said the assays will combine its micro-preparation cards for rapid sample preparation, micro channel-based microarrays for detecting nucleic acids, and its so-called "tentacle probes" for designing specific assays targeted at bio-threats.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.